Administration of CC-3 clinical trials

FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer

This study is testing a new medicine called CC-3 for people with advanced bowel, breast, or other cancers that haven't responded to usual treatments. It aims to see if CC-3 is safe and effective in fighting cancer by helping the body's immune system target cancer cells.